Novel Non-Absorbed Therapeutics

Relypsa is a clinical-stage biopharmaceutical company focused on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Enrollment of a pivotal Phase 3 trial of the company’s lead product candidate, patiromer, is complete, and upon FDA approval, Relypsa plans to commercialize the product as a treatment for hyperkalemia. Hyperkalemia is a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Patiromer is a non-absorbed, optimized potassium binding polymer administered as a convenient oral suspension powder that has been shown in clinical studies to be well tolerated as well as to lower, and maintain control of, serum potassium levels into the normal range in hyperkalemic subjects. Relypsa has global royalty-free commercialization rights to patiromer, and intellectual property protection in the U.S. until at least 2030.  


     2013 Annual Report to Stockholders